{
    "thread": {
        "uuid": "b6d3c7ebe17b185a026bf932be4da0fda04782aa",
        "url": "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-exceeds-market-returns:-some-facts-to-consider-0",
        "site_full": "www.nasdaq.com",
        "site": "nasdaq.com",
        "site_section": "https://www.nasdaq.com/feed/rssoutbound?category=Stocks",
        "site_categories": [
            "investing",
            "financial_news",
            "finance",
            "stocks"
        ],
        "section_title": "Stocks Feed",
        "title": "Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider",
        "title_full": "Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider",
        "published": "2024-01-06T01:00:00.000+02:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "news",
        "country": "US",
        "main_image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg",
        "performance_score": 0,
        "domain_rank": 751,
        "domain_rank_updated": "2024-01-02T12:06:49.000+02:00",
        "reach": null,
        "social": {
            "facebook": {
                "likes": 0,
                "comments": 0,
                "shares": 0
            },
            "gplus": {
                "shares": 0
            },
            "pinterest": {
                "shares": 0
            },
            "linkedin": {
                "shares": 0
            },
            "stumbledupon": {
                "shares": 0
            },
            "vk": {
                "shares": 0
            }
        }
    },
    "uuid": "b6d3c7ebe17b185a026bf932be4da0fda04782aa",
    "url": "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-exceeds-market-returns:-some-facts-to-consider-0",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Zacks",
    "published": "2024-01-06T01:00:00.000+02:00",
    "title": "Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider",
    "text": "In the latest trading session, Ligand Pharmaceuticals (LGND) closed at $70.83, marking a +0.67% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.18%. Meanwhile, the Dow experienced a rise of 0.07%, and the technology-dominated Nasdaq saw an increase of 0.1%.\nThe drugmaker's shares have seen an increase of 14.59% over the last month, surpassing the Medical sector's gain of 6.12% and the S&P 500's gain of 2.75%.\nThe upcoming earnings release of Ligand Pharmaceuticals will be of great interest to investors. The company's earnings per share (EPS) are projected to be $0.58, reflecting a 57.35% decrease from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $24.54 million, showing a 51.29% drop compared to the year-ago quarter.\nAny recent changes to analyst estimates for Ligand Pharmaceuticals should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.\nOur research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.\nThe Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.16% lower. Ligand Pharmaceuticals presently features a Zacks Rank of #4 (Sell).\nIn terms of valuation, Ligand Pharmaceuticals is presently being traded at a Forward P/E ratio of 15.92. This represents a discount compared to its industry's average Forward P/E of 22.55.\nThe Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 74, positioning it in the top 30% of all 250+ industries.\nThe Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.\nDon't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.\nOnly $1 to See All Zacks' Buys and Sells\nWe're not kidding.\nSeveral years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.\nThousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone.\nSee Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report To read this article on Zacks.com click here.\nThe views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
        "Health",
        "Science and Technology",
        "Economy, Business and Finance"
    ],
    "external_links": [
        "https://www.zacks.com/stock/news/2206595/ligand-pharmaceuticals-lgnd-exceeds-market-returns-some-facts-to-consider?cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_6v2-2206595",
        "https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_554&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_6v2-2206595",
        "https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=LGND&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_554&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_6v2-2206595",
        "https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/6328?adid=SYND_NASDAQ_ZU_ZU_TALEOFTAPE_554_01052024&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_6v2-2206595",
        "https://zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_554&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_6v2-2206595",
        "https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/6328",
        "https://zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=LGND&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_554&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_6v2-2206595",
        "https://zacks.com/stock/news/2206595/ligand-pharmaceuticals-lgnd-exceeds-market-returns-some-facts-to-consider?cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_6v2-2206595",
        "https://zacks.com/registration/ultimatetrader/welcome/eoffer/6328?adid=SYND_NASDAQ_ZU_ZU_TALEOFTAPE_554_01052024&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_6v2-2206595",
        "https://www.zacks.com/registration/pfp",
        "https://www.zacks.com/registration/pfp/",
        "https://www.zacks.com/stock/news/2206595/ligand-pharmaceuticals-lgnd-exceeds-market-returns-some-facts-to-consider"
    ],
    "external_images": [],
    "entities": {
        "persons": [],
        "organizations": [
            {
                "name": "ligand pharmaceuticals",
                "sentiment": "negative"
            },
            {
                "name": "s&p",
                "sentiment": "none"
            }
        ],
        "locations": []
    },
    "rating": null,
    "crawled": "2024-01-06T02:34:12.046+02:00",
    "updated": "2024-01-06T02:34:12.046+02:00"
}